The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.

<h4>Objective</h4>Two studies have reported that patients with the 4G/4G genotype of the plasminogen activator inhibitor-1 (PAI-1) genetic polymorphism had higher plasma PAI-1 concentrations and higher risk of death than those with the 4G/5G or 5G/5G genotypes; one study involved 175 chi...

Full description

Bibliographic Details
Main Authors: Leonardo Lorente, María M Martín, Juan M Borreguero-León, Ysamar Barrios, Jordi Solé-Violán, José Ferreres, Lorenzo Labarta, César Díaz, Alejandro Jiménez
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0129565
id doaj-6eae1e5d8c3e4ba08cda384327d9728e
record_format Article
spelling doaj-6eae1e5d8c3e4ba08cda384327d9728e2021-03-04T08:03:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01106e012956510.1371/journal.pone.0129565The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.Leonardo LorenteMaría M MartínJuan M Borreguero-LeónYsamar BarriosJordi Solé-ViolánJosé FerreresLorenzo LabartaCésar DíazAlejandro Jiménez<h4>Objective</h4>Two studies have reported that patients with the 4G/4G genotype of the plasminogen activator inhibitor-1 (PAI-1) genetic polymorphism had higher plasma PAI-1 concentrations and higher risk of death than those with the 4G/5G or 5G/5G genotypes; one study involved 175 children with meningococcal disease, and the other included 88 adult patients with septic shock. Thus, the objective of this study was to determine whether there is an association between carriage of the 4G/4G genotype, plasma PAI-1 concentrations and mortality in a large series of adult septic patients.<h4>Methods</h4>An observational, prospective, multicenter study was carried out in six Spanish Intensive Care Units including severe septic patients. We determined the PAI-1 4G/5G polymorphism and plasma PAI-1 concentrations in all patients. The end-points of the study were 30-day and 6-month mortality.<h4>Results</h4>We included a total of 260 patients, 82 (31.5%) with 4G/4G, 126 (48.5%) with 4G/5G and 52 (20.0%) with 5G/5G genotype. Multivariate logistic regression analysis showed that the 4G/4G genotype was associated with higher mortality at 30 days (Odds Ratio = 1.95; 95% CI = 1.063-3.561; p = 0.03) and at 6 months (Odds Ratio = 2.19; 95% CI = 1.221-3.934; p = 0.01), and that higher plasma PAI-1 concentrations were associated with higher mortality at 30 days (Odds Ratio = 1.01; 95% CI = 1.002-1.022; p = 0.02) at 6 months (Odds Ratio = 1.01; 95% CI = 1.003-1.023; p = 0.01). Multivariate linear regression analysis showed that increased plasma PAI-1 concentrations were associated with the PAI-1 4G/4G genotype (regression coefficient = 4.82; 95% CI = 3.227 to 6.406; p<0.001).<h4>Conclusions</h4>The major findings of our study, to our knowledge the largest series reporting data about 4G/5G polymorphism of the PAI-1 gene, plasma PAI-1 concentrations and mortality in septic patients, were that septic patients with the 4G/4G genotype had higher plasma PAI-1 concentrations and higher risk of death than those with 4G/5G or 5G/5G genotypes.https://doi.org/10.1371/journal.pone.0129565
collection DOAJ
language English
format Article
sources DOAJ
author Leonardo Lorente
María M Martín
Juan M Borreguero-León
Ysamar Barrios
Jordi Solé-Violán
José Ferreres
Lorenzo Labarta
César Díaz
Alejandro Jiménez
spellingShingle Leonardo Lorente
María M Martín
Juan M Borreguero-León
Ysamar Barrios
Jordi Solé-Violán
José Ferreres
Lorenzo Labarta
César Díaz
Alejandro Jiménez
The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
PLoS ONE
author_facet Leonardo Lorente
María M Martín
Juan M Borreguero-León
Ysamar Barrios
Jordi Solé-Violán
José Ferreres
Lorenzo Labarta
César Díaz
Alejandro Jiménez
author_sort Leonardo Lorente
title The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
title_short The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
title_full The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
title_fullStr The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
title_full_unstemmed The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
title_sort 4g/4g genotype of pai-1 polymorphism is associated with higher plasma pai-1 concentrations and mortality in patients with severe sepsis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description <h4>Objective</h4>Two studies have reported that patients with the 4G/4G genotype of the plasminogen activator inhibitor-1 (PAI-1) genetic polymorphism had higher plasma PAI-1 concentrations and higher risk of death than those with the 4G/5G or 5G/5G genotypes; one study involved 175 children with meningococcal disease, and the other included 88 adult patients with septic shock. Thus, the objective of this study was to determine whether there is an association between carriage of the 4G/4G genotype, plasma PAI-1 concentrations and mortality in a large series of adult septic patients.<h4>Methods</h4>An observational, prospective, multicenter study was carried out in six Spanish Intensive Care Units including severe septic patients. We determined the PAI-1 4G/5G polymorphism and plasma PAI-1 concentrations in all patients. The end-points of the study were 30-day and 6-month mortality.<h4>Results</h4>We included a total of 260 patients, 82 (31.5%) with 4G/4G, 126 (48.5%) with 4G/5G and 52 (20.0%) with 5G/5G genotype. Multivariate logistic regression analysis showed that the 4G/4G genotype was associated with higher mortality at 30 days (Odds Ratio = 1.95; 95% CI = 1.063-3.561; p = 0.03) and at 6 months (Odds Ratio = 2.19; 95% CI = 1.221-3.934; p = 0.01), and that higher plasma PAI-1 concentrations were associated with higher mortality at 30 days (Odds Ratio = 1.01; 95% CI = 1.002-1.022; p = 0.02) at 6 months (Odds Ratio = 1.01; 95% CI = 1.003-1.023; p = 0.01). Multivariate linear regression analysis showed that increased plasma PAI-1 concentrations were associated with the PAI-1 4G/4G genotype (regression coefficient = 4.82; 95% CI = 3.227 to 6.406; p<0.001).<h4>Conclusions</h4>The major findings of our study, to our knowledge the largest series reporting data about 4G/5G polymorphism of the PAI-1 gene, plasma PAI-1 concentrations and mortality in septic patients, were that septic patients with the 4G/4G genotype had higher plasma PAI-1 concentrations and higher risk of death than those with 4G/5G or 5G/5G genotypes.
url https://doi.org/10.1371/journal.pone.0129565
work_keys_str_mv AT leonardolorente the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT mariammartin the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT juanmborregueroleon the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT ysamarbarrios the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT jordisoleviolan the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT joseferreres the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT lorenzolabarta the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT cesardiaz the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT alejandrojimenez the4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT leonardolorente 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT mariammartin 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT juanmborregueroleon 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT ysamarbarrios 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT jordisoleviolan 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT joseferreres 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT lorenzolabarta 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT cesardiaz 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
AT alejandrojimenez 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis
_version_ 1714808161289895936